Lisa A. Carey

53.2k total citations · 12 hit papers
421 papers, 25.9k citations indexed

About

Lisa A. Carey is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lisa A. Carey has authored 421 papers receiving a total of 25.9k indexed citations (citations by other indexed papers that have themselves been cited), including 282 papers in Oncology, 224 papers in Cancer Research and 147 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lisa A. Carey's work include Breast Cancer Treatment Studies (184 papers), HER2/EGFR in Cancer Research (108 papers) and Cancer Treatment and Pharmacology (104 papers). Lisa A. Carey is often cited by papers focused on Breast Cancer Treatment Studies (184 papers), HER2/EGFR in Cancer Research (108 papers) and Cancer Treatment and Pharmacology (104 papers). Lisa A. Carey collaborates with scholars based in United States, Germany and Spain. Lisa A. Carey's co-authors include Charles M. Perou, Carey K. Anders, Eric P. Winer, Chad Livasy, Melissa A. Troester, Joseph Geradts, Elizabeth Claire Dees, Maggie C.U. Cheang, Robert C. Millikan and David W. Ollila and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Lisa A. Carey

405 papers receiving 25.4k citations

Hit Papers

Race, Breast Cancer Subtypes, and Survival in the Carolin... 2005 2026 2012 2019 2006 2007 2020 2005 2007 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
    2006 3.0k citations Lisa A. Carey, Charles M. Perou et al. JAMA profile →
  2. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
    2007 1.6k citations Lisa A. Carey, Dominic T. Moore et al. Clinical Cancer Research profile →
  3. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
    2020 851 citations Lisa A. Carey, Charles M. Perou et al. Journal of Clinical Oncology profile →
  4. Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
    2005 752 citations Lisa A. Carey et al. Journal of Clinical Oncology profile →
  5. Epidemiology of basal-like breast cancer
    2007 691 citations Robert C. Millikan, Patricia G. Moorman et al. Breast Cancer Research and Treatment profile →
  6. Triple-negative breast cancer: disease entity or title of convenience?
    2010 652 citations Lisa A. Carey, Eric P. Winer et al. Nature Reviews Clinical Oncology profile →
  7. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
    2014 650 citations Charles M. Perou, Sara M. Tolaney et al. Journal of Clinical Oncology profile →
  8. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
    2021 592 citations Lisa A. Carey, Sibylle Loibl et al. Journal of Clinical Oncology profile →
  9. Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
    2009 502 citations Carey K. Anders, Lisa A. Carey profile →
  10. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    2015 458 citations Sara M. Tolaney, Beverly Moy et al. profile →
  11. Triple negative breast cancer: Pitfalls and progress
    2022 384 citations Paola Zagami, Lisa A. Carey npj Breast Cancer profile →
  12. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
    2024 71 citations Aditya Bardia, Hope S. Rugo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa A. Carey United States 72 16.1k 12.1k 7.3k 5.4k 3.1k 421 25.9k
Fátima Cardoso Portugal 68 13.8k 0.9× 10.5k 0.9× 7.4k 1.0× 4.9k 0.9× 2.4k 0.8× 403 25.4k
Ana M. González-Angulo United States 83 15.2k 0.9× 11.4k 0.9× 8.9k 1.2× 5.2k 1.0× 3.8k 1.2× 281 25.2k
Jonas Bergh Sweden 73 15.6k 1.0× 11.6k 1.0× 11.2k 1.5× 4.9k 0.9× 2.8k 0.9× 521 29.1k
Antonio C. Wolff United States 71 15.9k 1.0× 10.7k 0.9× 5.5k 0.8× 4.9k 0.9× 3.4k 1.1× 360 24.8k
Edith A. Perez United States 79 20.7k 1.3× 11.1k 0.9× 6.6k 0.9× 5.8k 1.1× 2.5k 0.8× 400 30.1k
Steven Shak United States 54 16.7k 1.0× 11.2k 0.9× 8.1k 1.1× 5.6k 1.0× 3.3k 1.1× 133 28.1k
Karen A. Gelmon Canada 73 15.9k 1.0× 7.0k 0.6× 5.6k 0.8× 6.6k 1.2× 1.9k 0.6× 393 23.8k
Kathleen I. Pritchard Canada 72 15.6k 1.0× 9.9k 0.8× 6.1k 0.8× 5.4k 1.0× 2.4k 0.8× 369 25.4k
George W. Sledge United States 72 14.8k 0.9× 9.6k 0.8× 7.5k 1.0× 6.3k 1.2× 2.1k 0.7× 444 25.4k
Sibylle Loibl Germany 76 19.6k 1.2× 13.4k 1.1× 6.1k 0.8× 8.4k 1.6× 3.9k 1.2× 588 29.5k

Countries citing papers authored by Lisa A. Carey

Since Specialization
Citations

This map shows the geographic impact of Lisa A. Carey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa A. Carey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa A. Carey more than expected).

Fields of papers citing papers by Lisa A. Carey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa A. Carey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa A. Carey. The network helps show where Lisa A. Carey may publish in the future.

Co-authorship network of co-authors of Lisa A. Carey

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa A. Carey. A scholar is included among the top collaborators of Lisa A. Carey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa A. Carey. Lisa A. Carey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bailey, Christina E., et al.. (2025). Assessment of the functional and health-related needs of patients with metastatic breast cancer prior to initiation of cancer treatment. Breast Cancer Research and Treatment. 210(3). 539–550. 1 indexed citations
2.
Bardia, Aditya, Hope S. Rugo, Sara M. Tolaney, et al.. (2024). Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of Clinical Oncology. 42(15). 1738–1744. 71 indexed citations breakdown →
3.
Chen, Wendy Y., Karla V. Ballman, Ann H. Partridge, et al.. (2024). Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. 331(20). 1714–1714. 15 indexed citations
4.
Sella, Tal, Yue Zheng, Shoshana M. Rosenberg, et al.. (2023). Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. npj Breast Cancer. 9(1). 31–31. 3 indexed citations
5.
Zagami, Paola, Aranzazu Fernández-Martínez, Naim U. Rashid, et al.. (2023). Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer. JAMA Network Open. 6(12). e2348814–e2348814. 4 indexed citations
6.
Routh, Eric D., Amanda E.D. Van Swearingen, Maria J. Sambade, et al.. (2022). Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419. Frontiers in Oncology. 12. 818693–818693. 6 indexed citations
7.
Corti, Chiara, Gabriele Antonarelli, Carmine Valenza, et al.. (2022). Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?. European Journal of Cancer. 171. 25–42. 13 indexed citations
8.
9.
Carey, Lisa A.. (2021). Finding the positive in triple-negative breast cancer. Nature Cancer. 2(5). 476–478. 12 indexed citations
10.
Carey, Lisa A.. (2019). Research priorities in prediction of response in early breast cancer. The Breast. 48. S31–S33. 1 indexed citations
11.
Piccart, Martine, Giulia Viale, Peter Ellis, Marc Abramowicz, & Lisa A. Carey. (2016). ecancermedicalscience. ecancermedicalscience. 5. 217–217. 6 indexed citations
12.
Partridge, Ann H., R. Bryan Rumble, Lisa A. Carey, et al.. (2014). Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(29). 3307–3329. 194 indexed citations
13.
Deal, Allison M., Carey K. Anders, Aleix Prat, et al.. (2014). Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women. The Oncologist. 19(10). 1076–1083. 111 indexed citations
14.
Iglesia, Michael D., Benjamin G. Vincent, Joel S. Parker, et al.. (2014). Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. Clinical Cancer Research. 20(14). 3818–3829. 194 indexed citations
15.
Magbanua, Mark Jesus M., Lisa A. Carey, Amy DeLuca, et al.. (2014). Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research. 21(5). 1098–1105. 32 indexed citations
16.
Roll, J. Devon, Ashley G. Rivenbark, Rupninder Sandhu, et al.. (2013). Dysregulation of the epigenome in triple-negative breast cancers: Basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Experimental and Molecular Pathology. 95(3). 276–287. 47 indexed citations
17.
Carey, Lisa A.. (2012). HER2—a good addiction. Nature Reviews Clinical Oncology. 9(4). 196–197. 15 indexed citations
18.
Carey, Lisa A.. (2011). Directed Therapy of Subtypes of Triple-Negative Breast Cancer. The Oncologist. 16(S1). 71–78. 113 indexed citations
19.
Horton, Janet K., Jan Halle, Madlyn Ferraro, et al.. (2009). Radiosensitization of Chemotherapy-Refractory, Locally Advanced or Locally Recurrent Breast Cancer With Trastuzumab: A Phase II Trial. International Journal of Radiation Oncology*Biology*Physics. 76(4). 998–1004. 49 indexed citations
20.
Carey, Lisa A., Charles M. Perou, Chad Livasy, et al.. (2006). Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA. 295(21). 2492–2492. 2986 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fátima Cardoso Breakdown of academic impact, for papers by Ana M. González-Angulo Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Antonio C. Wolff Breakdown of academic impact, for papers by Edith A. Perez Breakdown of academic impact, for papers by Steven Shak Breakdown of academic impact, for papers by Karen A. Gelmon Breakdown of academic impact, for papers by Kathleen I. Pritchard Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Sibylle Loibl
Rankless by CCL
2026